Suppr超能文献

[巴西人群中用于治疗系统性动脉高血压和2型糖尿病的药物可及性:来自2019年巴西全国健康调查的数据]

[Access to medicines for the treatment of systemic arterial hypertension and type 2 diabetes mellitus in the Brazilian population: data from the 2019 Brazilian National Health Survey].

作者信息

Leal Adriana Amorim de Farias, Galvão Maria Helena Rodrigues, Roncalli Ângelo Giuseppe

机构信息

Universidade Federal do Rio Grande do Norte, Natal, Brasil.

Centro Universitário Unifacisa, Campina Grande, Brasil.

出版信息

Cad Saude Publica. 2024 Sep 16;40(8):e00241022. doi: 10.1590/0102-311XPT241022. eCollection 2024.

Abstract

This study aimed to measure access to medicines for the treatment of systemic arterial hypertension and type 2 diabetes mellitus in Brazil according to the mode of acquisition, as well as to analyze the factors associated with this access, based on data from the 2019 Brazilian National Survey of Health (PNS, acronym in Portuguese). Socioeconomic data and data related to the use of medicines by people aged 15 and over were analyzed in relation to access via the Brazilian Popular Pharmacy Program (PFPB, acronym in Portuguese) and via public services. The majority of Brazilians who took part in the PNS reported using medication to control hypertension in the previous 15 days (91.5%) and using oral medication for diabetes (95.2%) and/or insulin (70%). Most participants obtained oral medication for hypertension and type 2 diabetes mellitus via PFPB (45.2% and 53.6%, respectively), and the factors that most negatively influenced this access were older age, lower income, lower schooling, very poor self-rated health and not having private health insurance. Access to insulin, on the other hand, was most often via the public health service (69.7%), and the factors that most negatively influenced this access were black/mixed-race skin color, lower income, very poor self-rated health and not having private health insurance. Generally, the importance of the PFPB as a policy to increase access to essential medicines in Brazil was highlighted, considering the free supply of antihypertensive and antidiabetic drugs.

摘要

本研究旨在根据获取方式,衡量巴西治疗系统性动脉高血压和2型糖尿病药物的可及性,并基于2019年巴西全国健康调查(PNS,葡萄牙语缩写)的数据,分析与这种可及性相关的因素。分析了15岁及以上人群的社会经济数据以及与药物使用相关的数据,涉及通过巴西大众药房计划(PFPB,葡萄牙语缩写)和公共服务获取药物的情况。参与PNS的大多数巴西人报告称,在过去15天内使用药物控制高血压(91.5%),使用口服药物治疗糖尿病(95.2%)和/或胰岛素(70%)。大多数参与者通过PFPB获得高血压和2型糖尿病的口服药物(分别为45.2%和53.6%),对这种获取产生最大负面影响的因素是年龄较大、收入较低、受教育程度较低、自我评估健康状况很差以及没有私人健康保险。另一方面,胰岛素的获取最常通过公共卫生服务(69.7%),对这种获取产生最大负面影响的因素是黑人/混血肤色、收入较低、自我评估健康状况很差以及没有私人健康保险。总体而言,考虑到免费供应抗高血压和抗糖尿病药物,PFPB作为一项增加巴西基本药物可及性的政策的重要性得到了凸显。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83b9/11405024/31f2bb5ab572/1678-4464-csp-40-08-PT241022-gf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验